PRESS RELEASE:

Epeius Biotechnologies Corporation Receives $400,000 Grant to Support Gene Therapy Trials for Pancreatic Cancer

| From

SAN MARINO, CA - June 19 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the Company has been awarded a $400,000 grant by the Lazarex Cancer Foundation to expand and support ongoing cancer gene therapy clinical trials for advanced and metastatic pancreatic cancer.

Rexin-G(TM) is the world's first targeted injectable gene therapy vector to be approved for use in clinical trials in the USA and abroad. When injected intravenously, Rexin-G(TM) seeks out and destroys metastatic cancer, without the systemic toxicity generally associated with chemotherapy.

Rexin-G recently gained Orphan Drug status as an effective treatment for pancreatic cancer in the United States, and is currently available in clinical trials in Rochester MN.

In a statement to the press, Ms. Dana Dornsife, President of the Lazarex Cancer Foundation said: "We are pleased to provide Epeius Biotechnologies Corporation the funds needed to expedite the development of such promising genetic medicines, which - by improving both the survival and the quality of life - provide cancer patients with more quality time."

More information: http://www.epeiusbiotech.com

News Source:
Like, Share, Save this press release:
  TWEET   SHARE   G+   STUMBLE   LinkedIn   Instapaper   Buffer

PERMALINK:
https://www.send2press.com/newswire/2006-06-0619-001.shtml
  LEGAL NOTICE AND TERMS OF USE:  
The content of the above press release was provided by the “news source” (Epeius Biotechnologies Corporation) or authorized agency, who is solely responsible for its accuracy. Send2Press® is the originating wire service for this story and content is Copr. © 2006 Epeius Biotechnologies Corporation with newswire version Copr. © 2006 Send2Press (a service of Neotrope). All trademarks acknowledged.

Rights granted for reproduction by any legitimate news organization. However, if news is cloned/scraped verbatim, then original attribution must be maintained with link back to this page as “original syndication source.” Resale of this content for commercial purposes is prohibited without a license. Reproduction on any site selling a competitive service is also prohibited. Information is believed accurate, as provided by news source or authorized agency, however is not guaranteed, and you assume all risk for use of any information found herein/hereupon. This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.
STORY READS for this single page only, as of Sep 27 2016:
[ count retired 8.4.16 ]


back to top
REFERENCES: , , Rexin-G, Lazarex Cancer Foundation, clinical trials in the USA and abroad, destroys metastatic cancer, chemotherapy, Dana Dornsife, Dr. Erlinda M. Gordon, Dr. Frederick L. Hall, California, california news, news, press release from Epeius Biotechnologies Corporation, Jun 19, 2006, Funding and Investment, , , , , Epeius Biotechnologies Corporation Receives $400,000 Grant to Support Gene Therapy Trials for Pancreatic Cancer